Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Celcuity, Inc. stock logo
CELC
Celcuity
$13.79
+5.8%
$11.52
$7.58
$19.77
$522.18M0.45278,046 shs137,455 shs
GRAIL, Inc. stock logo
GRAL
GRAIL
$46.81
-1.6%
$40.79
$12.33
$63.99
$1.68BN/A1.20 million shs1.04 million shs
National HealthCare Co. stock logo
NHC
National HealthCare
$108.44
-0.3%
$103.46
$89.14
$138.49
$1.68B0.5559,879 shs49,044 shs
Progyny, Inc. stock logo
PGNY
Progyny
$21.45
+1.0%
$21.78
$13.39
$30.42
$1.84B1.311.71 million shs605,548 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Celcuity, Inc. stock logo
CELC
Celcuity
0.00%+9.97%+15.11%+59.42%-15.45%
GRAIL, Inc. stock logo
GRAL
GRAIL
0.00%-3.26%+17.01%+110.40%+4,681,399,900.00%
National HealthCare Co. stock logo
NHC
National HealthCare
0.00%+0.28%+3.89%+16.74%-2.69%
Progyny, Inc. stock logo
PGNY
Progyny
0.00%-2.10%+0.70%-5.09%-24.10%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Celcuity, Inc. stock logo
CELC
Celcuity
2.1556 of 5 stars
3.61.00.00.02.42.50.0
GRAIL, Inc. stock logo
GRAL
GRAIL
0.6821 of 5 stars
1.11.00.00.02.60.81.3
National HealthCare Co. stock logo
NHC
National HealthCare
N/AN/AN/AN/AN/AN/AN/AN/A
Progyny, Inc. stock logo
PGNY
Progyny
1.0768 of 5 stars
1.22.00.00.01.82.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Celcuity, Inc. stock logo
CELC
Celcuity
3.17
Buy$28.40105.95% Upside
GRAIL, Inc. stock logo
GRAL
GRAIL
2.25
Hold$31.50-32.71% Downside
National HealthCare Co. stock logo
NHC
National HealthCare
0.00
N/AN/AN/A
Progyny, Inc. stock logo
PGNY
Progyny
2.42
Hold$23.459.35% Upside

Current Analyst Ratings Breakdown

Latest CELC, PGNY, GRAL, and NHC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/1/2025
Celcuity, Inc. stock logo
CELC
Celcuity
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$30.00
6/30/2025
Celcuity, Inc. stock logo
CELC
Celcuity
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$29.00
5/19/2025
Celcuity, Inc. stock logo
CELC
Celcuity
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$27.00 ➝ $27.00
5/15/2025
Celcuity, Inc. stock logo
CELC
Celcuity
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$29.00 ➝ $29.00
5/14/2025
GRAIL, Inc. stock logo
GRAL
GRAIL
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$32.00 ➝ $43.00
5/12/2025
Progyny, Inc. stock logo
PGNY
Progyny
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$23.00 ➝ $21.00
4/21/2025
GRAIL, Inc. stock logo
GRAL
GRAIL
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$32.00
4/11/2025
Celcuity, Inc. stock logo
CELC
Celcuity
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$29.00 ➝ $29.00
(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Celcuity, Inc. stock logo
CELC
Celcuity
N/AN/AN/AN/A$3.11 per shareN/A
GRAIL, Inc. stock logo
GRAL
GRAIL
$125.60M13.41$28.90 per share1.62$74.50 per share0.63
National HealthCare Co. stock logo
NHC
National HealthCare
$1.37B1.22$6.92 per share15.68$59.41 per share1.83
Progyny, Inc. stock logo
PGNY
Progyny
$1.17B1.58$0.34 per share62.19$4.96 per share4.32
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Celcuity, Inc. stock logo
CELC
Celcuity
-$111.78M-$3.03N/AN/AN/AN/A-96.21%-49.44%8/13/2025 (Estimated)
GRAIL, Inc. stock logo
GRAL
GRAIL
-$2.03B-$60.99N/AN/AN/A-1,464.53%-17.99%-15.02%8/12/2025 (Estimated)
National HealthCare Co. stock logo
NHC
National HealthCare
$66.80M$6.9213.59N/A10.03%6.87%4.68%N/A
Progyny, Inc. stock logo
PGNY
Progyny
$54.34M$0.5737.6333.002.264.33%10.90%7.20%8/5/2025 (Estimated)

Latest CELC, PGNY, GRAL, and NHC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Celcuity, Inc. stock logo
CELC
Celcuity
-$0.95-$0.86+$0.09-$0.86N/AN/A
5/13/2025Q1 2025
GRAIL, Inc. stock logo
GRAL
GRAIL
-$4.03-$3.10+$0.93-$3.10$35.80 million$31.84 million
5/8/2025Q1 2025
Progyny, Inc. stock logo
PGNY
Progyny
$0.45$0.17-$0.28$0.17$307.86 million$324.04 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Celcuity, Inc. stock logo
CELC
Celcuity
N/AN/AN/AN/AN/A
GRAIL, Inc. stock logo
GRAL
GRAIL
N/AN/AN/AN/AN/A
National HealthCare Co. stock logo
NHC
National HealthCare
$2.562.36%N/A36.99%10 Years
Progyny, Inc. stock logo
PGNY
Progyny
N/AN/AN/AN/AN/A

Latest CELC, PGNY, GRAL, and NHC Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/8/2025
National HealthCare Co. stock logo
NHC
National HealthCare
quarterly$0.642.7%6/30/20256/30/20258/1/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Celcuity, Inc. stock logo
CELC
Celcuity
1.14
6.61
6.61
GRAIL, Inc. stock logo
GRAL
GRAIL
N/A
9.70
9.71
National HealthCare Co. stock logo
NHC
National HealthCare
0.14
1.80
1.77
Progyny, Inc. stock logo
PGNY
Progyny
N/A
2.39
2.39

Institutional Ownership

CompanyInstitutional Ownership
Celcuity, Inc. stock logo
CELC
Celcuity
63.33%
GRAIL, Inc. stock logo
GRAL
GRAIL
N/A
National HealthCare Co. stock logo
NHC
National HealthCare
56.44%
Progyny, Inc. stock logo
PGNY
Progyny
94.93%

Insider Ownership

CompanyInsider Ownership
Celcuity, Inc. stock logo
CELC
Celcuity
15.77%
GRAIL, Inc. stock logo
GRAL
GRAIL
1.85%
National HealthCare Co. stock logo
NHC
National HealthCare
14.97%
Progyny, Inc. stock logo
PGNY
Progyny
9.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Celcuity, Inc. stock logo
CELC
Celcuity
4037.87 million31.90 millionOptionable
GRAIL, Inc. stock logo
GRAL
GRAIL
1,36035.97 million35.31 millionOptionable
National HealthCare Co. stock logo
NHC
National HealthCare
12,40015.46 million13.32 millionN/A
Progyny, Inc. stock logo
PGNY
Progyny
31085.72 million77.66 millionOptionable

Recent News About These Companies

Analysts Set Progyny, Inc. (NASDAQ:PGNY) PT at $23.45
Progyny, Inc. (PGNY) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Celcuity stock logo

Celcuity NASDAQ:CELC

$13.79 +0.75 (+5.75%)
Closing price 07/3/2025 03:07 PM Eastern
Extended Trading
$13.79 0.00 (0.00%)
As of 07/3/2025 04:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

GRAIL stock logo

GRAIL NASDAQ:GRAL

$46.81 -0.75 (-1.57%)
Closing price 07/3/2025 03:56 PM Eastern
Extended Trading
$46.82 +0.00 (+0.00%)
As of 07/3/2025 04:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

National HealthCare stock logo

National HealthCare NYSE:NHC

$108.44 -0.32 (-0.29%)
As of 07/3/2025 03:30 PM Eastern

National HealthCare Corporation engages in the operation of services to skilled nursing facilities, assisted and independent living facilities, homecare and hospice agencies, and health hospitals. Its skilled nursing facilities offer licensed therapy services, nutrition services, social services, activities, and housekeeping and laundry services, as well as medical services prescribed by physicians; and rehabilitative services, such as physical, speech, respiratory, and occupational therapy for patients recovering from strokes, heart attacks, orthopedic conditions, neurological illnesses, or other illnesses, injuries, or disabilities. The company's medical specialty units comprise memory care units and sub-cute nursing units that provide specialized care and programs for persons with Alzheimer's or related disorders; and assisted living facilities offer personal care services and assistance with general activities of daily living, such as dressing, bathing, meal preparation, and medication management. Its independent living facilities offers specially designed residential units for the active and ambulatory elderly and provide various ancillary services for residents, including restaurants, activity rooms and social areas; and behavioral health services to both adults and geriatric patients with psychiatric, emotional, and addictive disorders. In addition, the company's homecare agencies assist those who wish to stay at home or in assisted living residences but still require some degree of medical care or assistance with daily activities; hospice agencies that provides hospice and palliative care; and operates pharmacies, as well as managed care insurance solutions. Further, it offers management, accounting, and financial services; and leases its properties to third party operators. The company was founded in 1971 and is based in Murfreesboro, Tennessee.

Progyny stock logo

Progyny NASDAQ:PGNY

$21.45 +0.21 (+0.99%)
Closing price 07/3/2025 01:23 PM Eastern
Extended Trading
$21.16 -0.29 (-1.33%)
As of 07/3/2025 04:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.